Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery DiseaseMark Y. Chan, Christopher P. Rusconi, Neal S. Kleiman et al.|Circulation|2008Cited by 130
First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary InterventionMauricio G. Cohen, Richard C. Becker, Drew A. Purdy et al.|Circulation|2010Cited by 98
Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudyThomas J. Povsic, William A. Wargin, John H. Alexander et al.|European Heart Journal|2011Cited by 43
A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trialThomas J. Povsic, John H. Alexander, Mauricio G. Cohen et al.|American Heart Journal|2011Cited by 36
Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial DesignThomas J. Povsic, Richard C. Becker, Mauricio G. Cohen et al.|Journal of Thrombosis and Thrombolysis|2011Cited by 26